Calliditas Therapeutics Ab's Customers Performance

Name: Calliditas Therapeutics Ab Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

CALT

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


CALT's Source of Revenues		During the corresponding time, Calliditas Therapeutics Ab recorded a revenue increase by 49.74 % year on year, While revenue at the Calliditas Therapeutics Ab's corporate clients • List of CALT Customers

for the same period Calliditas Therapeutics Ab recorded revenue increase by 49.74 % year on year,

• List of CALT Customers

Calliditas Therapeutics Ab's Business Units

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Calliditas Therapeutics Ab's Comment on Sales, Marketing and Customers

The company develops treatments for patients with conditions addressed by its products, including Nefecon and setanaxib. Nefecon is targeted at markets in the United States, the European Union, and the United Kingdom, with regulatory approvals granted or sought in these regions. It is primarily focused on patients with IgA nephropathy, as demonstrated by the Phase 3 NefIgArd clinical trial. Setanaxib is under development for patients with primary biliary cholangitis (PBC), squamous cell carcinoma of the head and neck (SCCHN), and Alport syndrome. The company collaborates with commercialization partners such as STADA for regulatory filings and marketing authorization in the EU and UK.

Calliditas Therapeutics Ab’s Comment on Sales, Marketing and Customers

CALT's Stock Performance relative to it's Customers

CALT's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Calliditas Therapeutics Ab	1,073.44	129.24	-50.11	85
SUBTOTAL	0.00	0.00	0.00	-

Sources: Calliditas Therapeutics Ab’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Calliditas Therapeutics Ab’s corporate clients.
For your research, we’ve provided 9 tables on Calliditas Therapeutics Ab corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.